Ads
related to: docetaxel and carboplatin breast cancer survival rate 20 years- Request A Rep
Request a Representative & Discover
More About Treatment Option.
- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Ordering Information
Find Out More About Ordering
A Treatment For Your Patients.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Nurses Station
Explore Resources Made For Nurses
To Learn About A mTNBC Treatment.
- Clinical Trial Design
Learn More About Clinical Trial
And Study Results Today.
- Request A Rep
Search results
Results From The WOW.Com Content Network
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP
The trial included 325 patients from across 28 countries.
Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
During the 20-year study period, 8.5 percent of women who had lumpectomies died from breast cancer, nine percent of women who had mastectomies died from the disease, and 8.5 percent of women who ...
Ads
related to: docetaxel and carboplatin breast cancer survival rate 20 years